Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 18:06:39 Source:politicsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Jon Wysocki dead at 53: Staind drummer passes away
Next:Justin Timberlake set to bring his The Forget Tomorrow World Tour to Australia in 2025
You may also like
- Yvette Fielding says her Most Haunted co
- Xi Proposes Eight Major Initiatives on China
- Xi Meets Chairman of Presidential Leadership Council of Yemen
- Xi Encourages Hungarian Youths to Learn More About China, Become Envoys of Friendship
- Ohio judge to rule Monday on whether the state’s abortion ban stands
- Xi Extends Spring Festival Greetings to All Chinese
- Xi Inspects Combat Readiness of Armed Forces
- Xi Meets United Russia Party Chairman Medvedev
- Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature